Evidence map›Paper›PMID 39640896›Full record

ArticleThe World Allergy Organization journal2024

Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment.

Duong Duc Pham, Ji-Hyang Lee, Hyouk-Soo Kwon, Woo-Jung Song, You Sook Cho, Hyunkyoung Kim, Jae-Woo Kwon, So-Young Park, Sujeong Kim, Gyu Young Hur and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Duong Duc PhamDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ji-Hyang LeeDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hyouk-Soo KwonDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Woo-Jung SongDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
You Sook ChoDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hyunkyoung KimDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jae-Woo KwonDepartment of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, South Korea.
So-Young ParkDivision of Pulmonary, Allergy and Critical Care Medicine, Chung-Ang University Gwangmyeong Hospital, South Korea.
Sujeong KimDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Gyu Young HurDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Byung Keun KimDepartment of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, South Korea.
Young-Hee NamDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.
Min-Suk YangDepartment of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea.
Mi-Yeong KimDepartment of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
Sae-Hoon KimDepartment of Internal Medicine, Division of Allergy and Clinical Immunology, Seoul National University Bundang Hospital, Seongnam, South Korea.
Byung-Jae LeeDepartments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Taehoon LeeDepartment of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
So Young ParkDepartment of Internal Medicine, Eulji University School of Medicine, Seoul, South Korea.
Min-Hye KimDepartment of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea.
Young-Joo ChoDepartment of Allergy and Clinical Immunology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, South Korea.
ChanSun ParkDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea.
Jae-Woo JungDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Han Ki ParkDepartment of Allergy and Clinical Immunology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.
Joo-Hee KimDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.
Ji-Yong MoonDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea.
Pankaj BhavsarNational Heart and Lung Institute, Imperial College London, United Kingdom.
Ian M AdcockNational Heart and Lung Institute, Imperial College London, United Kingdom.
Kian Fan ChungNational Heart and Lung Institute, Imperial College London, United Kingdom.
Tae-Bum KimDepartment of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Funding

Medical Research Council MR/T010371/1
6 · The paper itself

Abstract

Background: Limited understanding exists regarding the progression trajectory of severe eosinophilic asthma (SEA) patients on type 2 biologics therapies. Objective: We aim to explore distinct longitudinal phenotypes of these patients based on crucial asthma biomarkers. Methods: We enrolled 101 adult patients with SEA. Of these, 51 were treated with anti-IL5/IL5Rα or anti-IL5/IL5RαR antibody, and 50 with anti-IL-4Rα antibody. Multi-trajectory analysis, an extension of univariate group-based trajectory modeling, was used to categorize patients based on their trajectories of forced expiratory volume in 1 s (FEV Results: Among anti-IL5/IL5Rα antibody-treated patients, 2 clusters were identified. The cluster characterized by higher baseline BEC and lower FEV Conclusion: To optimally monitor treatment response in SEA patients on type 2 biologics, integrating longitudinal biomarker features is essential.

Indexed as

Multi-trajectory analysisSevere eosinophilic asthmaType 2 biologics

Identifiers

PMID39640896
PMCPMC11617764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.